PRECISION-BP: Rationale and design of a randomized factorial trial of sacubitril/valsartan timing in obesity-associated non-dipping hypertension
Year: 2026
Type: article
Study design: Study Protocol
Abstract: Background Nocturnal non-dipping blood pressure (BP) pattern, defined as a <10% reduction in nighttime vs. daytime BP, is common among treated hypertensive individuals and is independently associated with increased cardiovascular risk. Obesity is associated with a high prevalence of non-dipping nocturnal BP and lower circulating natriuretic peptide (NP) levels. Given the role of NPs in circadian BP regulation, obesity-related disruption of NP-BP rhythmicity may contribute to impaired nocturnal BP dipping. Chronotherapy using timed administration of NP-augmenting sacubitril/valsartan (LCZ696) may restore these biological rhythms and improve the nocturnal BP dipping profile. Methods PRECISION-BP is an ongoing, double-blind, randomized, 2 × 2 factorial clinical trial, enrolling 160 obese hypertensive adults with non-dipping nocturnal BP, and without established cardiovascular disease. Participants are randomized in a 1:1:1:1 manner to one of these groups: A) morning dose strategy + LCZ696 49/51 mg (N=40), B) morning dose strategy + valsartan 80 mg (N=40), C) evening dose strategy + LCZ696 49/51mg (N=40), D) evening dose strategy + valsartan 80 mg (N=40) for 28 days. Participants undergo two 24-hour inpatient visits with serial blood sampling and continuous ambulatory BP monitoring, before and after 28 days of treatment. Planned analysis The primary endpoint is the change in the mean nocturnal systolic BP from baseline. Secondary exploratory endpoints include changes in nocturnal dipping, ambulatory BP parameters, and circulating and urinary biomarkers of NP biology and cardiovascular physiology. Conclusion PRECISION-BP will evaluate whether chronotherapy with sacubitril/valsartan improves nocturnal BP patterns and provide mechanistic insights into NP-mediated regulation of BP rhythmicity in obesity-associated non-dipping hypertension. Trial Status The trial started recruitment in February 2022. It has enrolled 159 participants as of 11 th August, 2026 and is ongoing. Clinical trial registration (Clinicaltrials.gov) NCT04971720
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $1,900
Awards: Atrial Natriuretic Peptide and Regulation of Cardiometabolic Health: A Genotype-Guided Human Physiological Study, CTSA UM1 at the University of Alabama at Birmingham, Mentored Patient-Oriented Research in Natriuretic Peptide System Based Precision Cardiometabolic Health, Clinical Implementation of Blood Pressure Polygenic Risk Score: A Randomized Clinical Trial, Natriuretic Peptide-Renin-Angiotensin-Aldosterone System Rhythm Axis and Nocturnal Blood Pressure, The Effects of Neprilysin Inhibition on Cardiometabolic Health in Black Individuals
OpenAlex ID: W7204269385
